The UK-based biopharmaceutical company AstraZeneca has filed a lawsuit in the Delhi High Court against Dr Reddy’s Laboratories to stop the company from launching the generic versions of Brilinta, reported The Economic Times.
The court on Tuesday asked the Indian drug maker to file a reply to the lawsuit and will hear its arguments on July 31, the report said quoting the lawyers aware of developments, adding that until then, Dr Reddy’s is not allowed to launch its generic version of the drug.
Copies of the drug can be manufactured only after all the patents covering it expire, AstraZeneca’s counsel argued in court, the daily said.
The AstraZeneca drug, Brilinta, is used to reduce chances of heart attacks or strokes by preventing blood clots in vessels, achieved over $1billion in global sales, it added.
One of AstraZeneca’s key patents for Brilinta expired in India this month and it has triggered the launch opportunities for local drug makers. The company, however, argued that one patent is still valid and effectively bars commercial launches of copies, the report said.